Meeting
2022 ASCO Annual Meeting
Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapy.
Authors
Amelia M. Taylor
Melanoma Institute Australia, Sydney, Australia
Amelia M. Taylor , Claire Galea , Serigne N. Lo , Florentia Dimitriou , Sarah Jacques , Clara Allayous , Hui-Ling Yeoh , Julia M. Ressler , Katharina C. Kähler , Lucia Festino , Julia Katharina Schwarze , Alexandre M. Wicky , Joanna Placzke , Douglas Buckner Johnson , Lisa Zimmer , Celeste Lebbe , Reinhard Dummer , Matteo S. Carlino , Georgina V. Long , Alexander M. Menzies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9575)
DOI
10.1200/JCO.2022.40.16_suppl.9575
Abstract #
9575
Poster Bd #
168
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2019 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
First Author: Emilia Nan Tie